



The Impact of the Dobbs Decision on Cancer Care: Patient Advocacy Perspective

August 31, 2023

Lisa Schlager | Vice President, Public Policy



FORCE

Facing Hereditary Cancer EMPOWERED

FORCE improves the lives

of the millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers.

Our community includes people with a BRCA, ATM, PALB2, CHEK2, PTEN or other inherited gene mutation and those diagnosed with Lynch syndrome.


Hereditary Cancer Genetic Mutations

Limited Gene Testing

BRCA



Lynch Syndrome



Multigene Panel Testing



Cancers Linked to Inherited Mutations

Cancer	Genes
Breast cancer in women	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, CDH1, NF1, NBN, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
Breast cancer in men	BRCA1, BRCA2, CHEK2, PALB2
Colorectal cancer	EPCAM, MLH1, MSH2, MSH6, PMS2, CHEK2, PTEN, STK11, TP53, MUTYH
Endometrial cancer	EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, STK11
Fallopian tube, ovarian, primary peritoneal cancer	ATM, BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, RAD51C, RAD51D, STK11
Gastric cancer	APC, CDH1, STK11, EPCAM, MLH1, MSH2, MSH6, PMS2
Melanoma	BAP1, BRCA2, CDK4, CDKN2A, PTEN, TP53
Pancreatic cancer	ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, TP53
Prostate cancer	ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, PALB2, PMS2



**Inherited Mutations and Cancer Risk Can be
Passed from Parents to Children**



**Hereditary Cancers Tend to Develop
at Younger Ages**

Medical Guidelines & Recommendations



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2024 Gene Summary: Risks and Management

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

CANCER RISK MANAGEMENT BASED ON GENETIC TEST RESULTS^{a,1,2}

The inclusion of a gene in this table below does not imply the endorsement either for or against multi-gene testing for moderate-penetrance genes.

“Recommend RRSO, typically between 35 and 40 years, recognizing that childbearing is a consideration. Because ovarian cancer onset in patients with BRCA2 P/LP variants is an average of 8–10 years later than in patients with BRCA1 P/LP variants, it is reasonable to delay RRSO for management of ovarian cancer risk until age 40–45 years in patients with BRCA2 P/LP variants unless age at diagnosis in the family warrants earlier age for consideration of prophylactic surgery.”

- American Academy of Pediatrics
- American Society of Clinical Oncology
- American Society for Reproductive Medicine
- American College of Obstetricians and Gynecologists
- National Comprehensive Cancer Network
- European Society of Clinical Oncology

Patient Advocacy Efforts

- **Federal Employee Health Plans** - 2023, Federal employees have insurance coverage for fertility preservation and four plan options that cover Assisted Reproductive Technology (ART)
- **State Laws** - 15 states have laws covering fertility preservation for cancer patients and others facing infertility due to medical treatment or surgery (iatrogenic infertility)
- **Federal Legislation** - Comprehensive Cancer Survivorship Act (CCSA) aims to provide Medicaid coverage of fertility preservation services for individuals diagnosed with cancer undergoing treatment for such cancer that may lead to iatrogenic (medically induced) infertility




Image credit: Alliance for Fertility Preservation

Connect with FORCE

Website: FacingOurRisk.org
Helpline: 866-288-RISK
Email: info@FacingOurRisk.org
Get Social: FacingOurRisk



Lisa Schlager,
Vice President, Public Policy
Email: lisas@facingourrisk.org
Phone: 301-961-4956

